This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Randomized Controlled Trial  • Rheumatoid Arthritis  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2008;299(1):28.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A previously halted gene therapy trial for the treatment of rheumatoid arthritis has been given the green light to resume.

The trial, conducted by Seattle-based Targeted Genetics Corporation, was shut down this summer after Jolee Mohr, aged 36 years, died 3 weeks after receiving a gene therapy injection to treat inflammatory arthritis. Mohr enrolled in this phase 1/2 trial of a new gene therapy, which involved injections of an adeno-associated virus vector carrying a gene coding for a protein that inhibits tumor necrosis factor (TNF-), a proinflammatory cytokine. Mohr received an initial injection in her right knee in February and a second in July.

At a September meeting of the National Institutes of Health Recombinant DNA Advisory Committee (RAC), experts determined that the patient apparently died because she had a severely compromised immune system and succumbed to a fungal infection. Mohr's liver, lungs, and other tissues were . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?